Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von YouTube.
Mehr erfahren

Video laden


Izbrunch 02

Prof. Hanna Taipaleenmäki
Institute of Musculoskeletal Medicine (IMM), Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich


Topic: Novel targets to treat musculoskeletal disorders
Musculoskeletal diseases affect people from children to elderly. At IMM we investigate bone and muscle physiology and pathology combining molecular- and cell biology, pre-clinical models and patient care. Our approach to better understand the disease mechanisms and to identify novel targets to treat musculoskeletal disorders will be discussed during this IZBrunch

Izbrunch 01

Dr. Jonas Helma-Smets
CSO Tubulis GmbH


Topic: Tubulis – Developing the next generation of Antibody-Drug Conjugates (ADCs) for targeted cancer therapies
Tubulis has developed a suite of complementary technology platforms for the discovery and development of a new generation of versatile and customizable antibody-drug conjugates (ADCs) for targeted cancer therapy. At the heart of our proprietary platforms are completely new conjugation technologies, that allow us to overcome the main limitations of ADC technologies to date.

Welcome & Moderation


Dr. Peter Hanns Zobel
Managing Director of the IZB

News of the IZB